about
Role of kappa-opioid receptors in stress and anxiety-related behavior.Drug withdrawal conceptualized as a stressor.Molecular switches of the κ opioid receptor triggered by 6'-GNTI and 5'-GNTI.Kappa Opioids, Salvinorin A and Major Depressive DisorderKappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine NeuronsCharacterization of BU09059: a novel potent selective κ-receptor antagonistStilbenes as κ-selective, non-nitrogenous opioid receptor antagonistsAblation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticityDiscovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonistsStructure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid ReceptorSelective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice.Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.Kappa Antagonist JDTic in Phase 1 Clinical Trial.Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens.Beyond serotonin: newer antidepressants in the future.The kappa opioid receptor: from addiction to depression, and back.Activation of κ-opioid receptor by U50,488H improves vascular dysfunction in streptozotocin-induced diabetic rats.Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motifAbnormal error processing in depressive states: a translational examination in humans and ratsEffects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptorA Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.Dynorphin, Dysphoria, and Dependence: the Stress of AddictionHow does stress-induced activation of the kappa opioid system increase addiction risk?Generation of a KOR-Cre knockin mouse strain to study cells involved in kappa opioid signalingEffects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice.Prefrontal Cortical Kappa Opioid Receptors Attenuate Responses to Amygdala Inputs.Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.Neoclerodanes as atypical opioid receptor ligandsKappa-opioid receptors differentially regulate low and high levels of ethanol intake in female mice.Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversionHypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area.Effects of Chronic Social Defeat Stress on Sleep and Circadian Rhythms Are Mitigated by Kappa-Opioid Receptor Antagonism.Mechanism Governing Human Kappa-Opioid Receptor Expression under Desferrioxamine-Induced Hypoxic Mimic Condition in Neuronal NMB Cells.Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ Opioid Receptor.Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analoguesCombined administration of buprenorphine and naltrexone produces antidepressant-like effects in miceKappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships.
P2860
Q26991739-581E21BD-1668-4F2E-9EBE-924AD5896992Q26997989-E33A191C-6989-4D88-954F-C15A19960A17Q27302413-E12164E4-5C27-401B-815C-DAD53643ECC6Q28075656-207BA283-83B8-41D3-8EC3-834C5AF8112AQ28267475-4F6C6B2F-DDC1-44EC-A426-52141BD4DC15Q28305606-D28257DA-C07B-47A9-ABCA-460F306DADD8Q28306481-88573279-1D7A-4D19-A825-7BE81C9C5A0CQ30435816-CEB7CE06-EAEA-4ED4-99D8-D5FBDA3CBF89Q30436776-AC3C7DEE-7B34-4F59-9594-D36B3411406EQ33860286-263018AA-A14D-4E01-AED4-457C362AB9BFQ33911524-A96945F9-0967-4352-A3FA-361ED3338310Q34409641-5029BA4B-5616-4309-B35B-224FE5D05A0EQ34485042-4822B293-4AF0-4EFE-9179-C854FC98D275Q34499320-9D0E3B46-ECA1-4C9A-85C9-59599481A434Q34557706-A0C6EA4C-31D2-486D-9D6E-E18B53AF88B8Q34650892-2EBFF1DE-FFCD-4942-A5DE-61172D9A7A61Q35166507-67C2F920-8319-4734-BD0D-85B9191142A8Q35744300-32C4BB41-208A-4C29-B3FB-BAFAEEE4B94DQ35753180-32599DBB-6F0C-4EDD-9399-BF0BBFC27D0DQ35956317-0174743E-C67F-48A1-87D0-E7564E410677Q36103013-76CD60C3-9FB5-4F4E-855E-AE3CA64F1907Q36184879-9C93F954-FA67-42C4-A90C-8EA595089C9EQ36366791-3CBEF99D-3234-4E0D-94CA-3E099B09ED24Q36384633-8EF1902D-9BD3-46DD-B3E6-2FB4938501CDQ36561843-F3992E3E-ADD7-4A3B-86B4-327EDE4DD8EFQ36616908-EF50E390-332A-457B-A227-5C12E97E0FD3Q36894439-6624C01B-D439-40D1-B559-945D255569D8Q36894509-AC44647B-C5D2-4FD6-8E7C-532B673DBD52Q36899819-151BF7A1-5576-4573-895E-248D2AF98741Q37283069-8D7A35D2-2F9E-4057-9E24-BDF6AEE435A9Q37309739-2108FD2C-38BE-42AA-8705-75468F42D7DDQ37725194-8534B4C7-1398-4719-A211-AAA17E7DAAF7Q38695245-A2C3F746-04D2-4466-9537-4BA151E49D98Q38719740-25B8DB26-1291-4E36-A504-B91456449995Q38734980-08193CA3-A7D2-4EE1-AFC1-A08A40497704Q38855312-EEA3CDD0-0662-452C-BA2D-0993236514E0Q39033568-98CD7CBA-2ED5-4D51-B722-90CADA059767Q41537125-AD74F270-5A49-4D41-ABA1-3646918066CAQ41639865-B126976F-43C7-4375-8484-810AA4081F4DQ41722010-077F7EB3-FD8E-4D10-9D40-88F59651ABAC
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Development of κ opioid receptor antagonists.
@ast
Development of κ opioid receptor antagonists.
@en
type
label
Development of κ opioid receptor antagonists.
@ast
Development of κ opioid receptor antagonists.
@en
prefLabel
Development of κ opioid receptor antagonists.
@ast
Development of κ opioid receptor antagonists.
@en
P2860
P356
P1476
Development of κ opioid receptor antagonists.
@en
P2093
F Ivy Carroll
William A Carlezon
P2860
P304
P356
10.1021/JM301783X
P407
P577
2013-02-14T00:00:00Z